Categories: DNANews

Zymo Research Stands by Its Innovative cfDNA Technology in Response to Qiagen’s Lawsuit

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

IRVINE, Calif., Sept. 18, 2024 /PRNewswire/ — Zymo Research Corporation, a leader in innovative life science solutions, acknowledges the patent infringement lawsuit filed by Qiagen GmbH on August 20, 2024, at the US District Court for the Central District of California regarding its MAGicBead cfDNA isolation technology. Zymo Research respects intellectual property rights and is confident that this technology represents a significant advancement in nucleic acid purification.

“Our MAGic cfDNA purification system is a groundbreaking innovation,” said Dr. Larry Jia, Founder and CEO of Zymo Research. “While this legal challenge places a significant burden on our resources as a small company, our commitment to the scientific community is stronger than ever.”

For over 30 years, Zymo Research, a company of “Scientists for Scientists,” has delivered innovative solutions to meet the evolving needs of researchers. Despite being a modestly sized company with around 250 employees, Zymo Research offers cutting-edge solutions from genetic, epigenetic, and microbiomic research tools to eco-friendly sample transport solutions. This is owed to prioritizing a culture of innovation, quality, and customer service.

“Our success is rooted in the trust of our customers and researchers worldwide,” said Dr. Marc Van Eden, VP of Corporate Development. “We are committed to giving back to the community with the best, most innovative products.”

Despite this legal challenge, Zymo Research remains focused on its mission of advancing life science with reliable solutions trusted by thousands of researchers globally and serves as a reminder of their unwavering commitment to science and the betterment of humanity.

About Zymo Research

Zymo Research, a privately owned biotech company founded in 1994, is a global leader in molecular tools for life sciences. Driven by the principle “The Beauty of Science is to Make Things Simple,” Zymo Research is dedicated to developing innovative solutions that address complex scientific challenges. Known also as The Epigenetics Company, Zymo Research offers a comprehensive range of technologies, including solutions for sample collection, DNA/RNA purification, NGS library preparation, microbiomics, transcriptomics, epigenomics, genomics, and Next-Generation Sequencing (NGS) services.

Through scientific innovation, Zymo Research is committed to engineering sustainable biotech solutions that fundamentally change how life science research is conducted– as demonstrated by their ambient temperature sample collection and transportation DNA/RNA Shield system, which eliminate cold chain logistics completely, thus reducing waste and the environmental footprint.

For more information, please visit www.zymoresearch.com and follow on Facebook, LinkedIn, X (Twitter), and Instagram

View original content to download multimedia:https://www.prnewswire.com/news-releases/zymo-research-stands-by-its-innovative-cfdna-technology-in-response-to-qiagens-lawsuit-302251177.html

SOURCE Zymo Research Corp.

Staff

Recent Posts

Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements

1-for-60 reverse stock split to become effective as of the opening of trading on June…

3 hours ago

Sharecare introduces new interactive solutions to elevate health literacy and increase condition-specific treatment adherence

Utilizing augmented reality, artificial intelligence, and time-based visualization, Sharecare’s newest innovative tools help life sciences…

3 hours ago

RadioMedix Debuts Proprietary bench top ²¹²Pb Generator to Support Targeted Alpha Therapy Development

New bench top ²¹²Pb generator to expand clinical-grade isotope supply for targeted alpha therapy research…

3 hours ago

Fortrea Adopts Limited-Duration Stockholder Rights Plan

Board Committed to Protecting Long-Term Value for All StockholdersDURHAM, N.C., June 12, 2025 (GLOBE NEWSWIRE)…

3 hours ago

Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle…

3 hours ago

Fortrea Adopts Limited-Duration Stockholder Rights Plan

Board Committed to Protecting Long-Term Value for All StockholdersDURHAM, N.C., June 12, 2025 (GLOBE NEWSWIRE)…

3 hours ago